We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+12.67%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.74B
AUM Growth
+$261M
Cap. Flow
+$250M
Cap. Flow %
14.34%
Top 10 Hldgs %
44.01%
Holding
80
New
16
Increased
10
Reduced
40
Closed
8

Top Buys

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$111M
2
BBIO icon
BridgeBio Pharma
BBIO
+$75.8M
3
STOK icon
Stoke Therapeutics
STOK
+$50.2M
4
QURE icon
uniQure
QURE
+$38.2M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$25.4M

Top Sells

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$34.5M
2
ZGNX
Zogenix, Inc.
ZGNX
+$24.8M
3
ASND icon
Ascendis Pharma A/S
ASND
+$23.9M
4
ARGX icon
argenx
ARGX
+$15.9M
5
ANAB icon
AnaptysBio
ANAB
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 88.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RUBY
51
DELISTED
Rubius Therapeutics, Inc
RUBY
$9.44M 0.54%
600,000
-50,000
-8% -$807K
HARP
52
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$8.45M 0.49%
64,999
-2,390
-4% -$278K
BCEL
53
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$8.38M 0.48%
+444,942
New +$8.03M
ATRA icon
54
Atara Biotherapeutics
ATRA
$75.5M
$8.04M 0.46%
16,000
-6,000
-27% -$4.24M
QURE icon
55
CALL
uniQure
QURE
$3.03B
$7.82M 0.45%
+100,000
New +$6.37M
KZR
56
DELISTED
Kezar Life Sciences
KZR
$7.47M 0.43%
96,829
-33,171
-26% -$5.16M
GNFT
57
DELISTED
Genfit
GNFT
$6.31M 0.36%
319,700
-30,300
-9% -$709K
DTIL icon
58
Precision BioSciences
DTIL
$180M
$6.2M 0.36%
15,584
-10,417
-40% -$4.19M
QTTB icon
59
Q32 Bio
QTTB
$466M
$5.87M 0.34%
+16,667
New +$6.55M
IFRX icon
60
InflaRx
IFRX
$250M
$4.74M 0.27%
1,500,000
-1,090,000
-42% -$34.5M
TECX
61
Tectonic Therapeutic
TECX
$529M
$4.47M 0.26%
22,917
-2,083
-8% -$449K
NBIX icon
62
Neurocrine Biosciences
NBIX
$16.8B
$4.22M 0.24%
50,000
-40,000
-44% -$3.28M
NERV icon
63
Minerva Neurosciences
NERV
$185M
$3.42M 0.2%
75,988
– –
BOLD
64
DELISTED
Audentes Therapeutics, Inc
BOLD
$2.84M 0.16%
75,000
-25,000
-25% -$960K
ITRM
65
DELISTED
Iterum Therapeutics
ITRM
$2.73M 0.16%
26,426
-127
-0.5% -$14.1K
SRRK icon
66
Scholar Rock
SRRK
$5.67B
$2.38M 0.14%
150,000
-28,891
-16% -$535K
ABEO icon
67
Abeona Therapeutics
ABEO
$366M
$1.67M 0.1%
14,000
-2,000
-13% -$335K
XLRN
68
DELISTED
Acceleron Pharma
XLRN
$1.64M 0.09%
40,000
– –
ACRS icon
69
Aclaris Therapeutics
ACRS
$726M
$548K 0.03%
250,000
-170,555
-41% -$930K
OTLKW
70
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$46K ﹤0.01%
416,666
– –
OTLK icon
71
Outlook Therapeutics
OTLK
$183M
$32K ﹤0.01%
+788
New +$36.7K
CLRBW
72
DELISTED
Cellectar Biosciences, Inc.
CLRBW
$3K ﹤0.01%
52,999
– –
COLL icon
73
Collegium Pharmaceutical
COLL
$1.15B
– –
-200,000
Closed -$3.03M
HRTX icon
74
Heron Therapeutics
HRTX
$93.9M
– –
-150,000
Closed -$3.67M
INCY icon
75
Incyte
INCY
$24.2B
– –
-30,000
Closed -$2.58M
1 2
3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q2 2019 Portfolio in Review

As of Q2 2019, Cormorant Asset Management held 80 positions worth $1.74B, up 18% from $1.48B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Cormorant Asset Management deployed $250M of net new capital in Q2 2019, opening 16 new positions and adding to 10 existing holdings. Its largest new stake was Turning Point Therapeutics, Inc. Common Stock: 3,122,367 shares worth $127M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was InflaRx, an estimated $34.5M trimmed.

  • Cormorant Asset Management's largest Q2 2019 buy was Turning Point Therapeutics, Inc. Common Stock: 3,122,367 shares worth $127M.
  • Cormorant Asset Management added most to Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019, an estimated $25.4M increase.
  • Cormorant Asset Management's biggest Q2 2019 reduction was InflaRx, cutting an estimated $34.5M.
  • Cormorant Asset Management fully exited Zogenix, Inc. in Q2 2019, selling an estimated $24.8M.
  • Cormorant Asset Management's ten largest holdings make up 44% of its $1.74B portfolio in Q2 2019.
  • Cormorant Asset Management opened 16 new positions and closed 8 in Q2 2019.
  • Cormorant Asset Management's portfolio value rose 18% quarter-over-quarter to $1.74B.

Based on Cormorant Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.